Free, no obligation
Tell us about your asset and target country. We respond within 1 business day, then follow with a detailed FIH plan: regulatory pathway, site selection, indicative timeline, and indicative budget — at no cost to you.
We take on a limited number of new FIH programs each quarter.
We respond within 1 business day of your submission. Your detailed roadmap follows once we have reviewed your details; we will tell you upfront what to expect for your case.
Yes. There is no cost and no obligation. The roadmap is yours to keep whether or not you engage bioaccess® to run the trial.
Our lead FIH execution jurisdictions (Panama, El Salvador, Chile, and the Dominican Republic), other Latin American countries on request, plus U.S. regulatory anchoring (FDA Pre-Sub, IND, IDE). We recommend the optimal execution country based on your asset, indication, and regulatory goals.
Your asset (device, drug, or biologic), the indication, your target country or "recommend one," your expected patient count, and your preferred timeline window. The form takes about 3 minutes to complete.
You can act on it independently, share it with your board, or schedule a 30-minute review call with our team — your choice. We will not pressure you to engage bioaccess® for execution.